Kiniksa Pharmaceuticals International, plc
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M |
| Operating income | $77.2M | -$45.6M | -$25.2M | $9.8M | -$156.6M |
| Cost of revenue | $77.7M | $60.9M | $33.4M | $22.9M | $9.1M |
| Cash from operations | $138.0M | $25.7M | $13.3M | $5.8M | -$126.3M |
| Capital expenditure | $1.6M | $277,000 | $130,000 | $105,000 | $415,000 |
| Free cash flow | $136.4M | $25.4M | $13.2M | $5.7M | -$126.7M |
| Impairments | $0 | — | — | — | — |
| Total assets | $763.6M | $580.6M | $526.3M | $459.7M | $232.8M |
| Total liabilities | $196.0M | $142.1M | $87.5M | $63.5M | $47.8M |
Shares outstanding 76.9M · Free float 46.5%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.